VVValerio Verdiani

Valerio Verdiani

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Valerio Verdiani has a total of 72 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comparison and combination of a hemodynamics/biomarkers-based model with simplified PESI score for prognostic stratification of acute pulmonary embolism: findings from a real world study

    by Luca Masotti, Grazia Panigada, Giancarlo Landini, Filippo Pieralli, Francesco Corradi, Salvatore Lenti, Rino Migliacci, Carlo Nozzoli, Maddalena Grazzini, Lucia Ciucciarelli, et al.

    Background: Prognostic stratification is of utmost importance for management of acute Pulmonary Embolism (PE) in clinical practice. Many prognostic models have been proposed, but which is the best prognosticator in real life remains unclear. The aim of our study was to compare and combine the predictive values of the hemodynamics/biomarkers based prognostic model proposed by European Society of Cardiology (ESC) in 2008 and simplified PESI score (sPESI). Methods: Data records of 452 patients discharged for acute PE from Internal Medicine wards of Tuscany (Italy) were analysed. The ESC model and sPESI were retrospectively calculated and compared by using Areas under Receiver Operating Characteristics (ROC) Curves (AUCs) and finally the combination of the two models was tested in hemodinamically stable patients. All cause and PE-related in-hospital mortality and fatal or major bleedings were the analyzed endpoints Results: All cause in-hospital mortality was 25% (16.6% PE related) in high risk, 8.7% (4.7%) in intermediate risk and 3.8% (1.2%) in low risk patients according to ESC model. All cause in-hospital mortality was 10.95% (5.75% PE related) in patients with sPESI score ≥1 and 0% (0%) in sPESI score 0. Predictive performance of sPESI was not significantly different compared with 2008 ESC model both for all cause (AUC sPESI 0.711, 95% CI: 0.661-0.758 versus ESC 0.619, 95% CI: 0.567-0.670, difference between AUCs 0.0916, p=0.084) and for PE-related mortality (AUC sPESI 0.764, 95% CI: 0.717-0.808 versus ESC 0.650, 95% CI: 0.598-0.700, difference between AUCs 0.114, p=0.11). Fatal or major bleedings occurred in 4.30% of high risk, 1.60% of intermediate risk and 2.50% of low risk patients according to 2008 ESC model, whereas these occurred in 1.80% of high risk and 1.45% of low risk patients according to sPESI, respectively. Predictive performance for fatal or major bleeding between two models was not significantly different (AUC sPESI 0.658, 95% CI: 0.606-0.707 versus ESC 0.512, 95% CI: 0.459-0.565, difference between AUCs 0.145, p=0.34). In hemodynamically stable patients, the combined endpoint in-hospital PE-related mortality and/or fatal or major bleeding (adverse events) occurred in 0% of patients with low risk ESC model and sPESI score 0, whilst it occurred in 5.5% of patients with low-risk ESC model but sPESI ≥1. In intermediate risk patients according to ESC model, adverse events occurred in 3.6% of patients with sPESI score 0 and 6.65% of patients with sPESI score ≥1. Conclusions: In real world, predictive performance of sPESI and the hemodynamic/biomarkers-based ESC model as prognosticator of in-hospital mortality and bleedings is similar. Combination of sPESI 0 with low risk ESC model may identify patients with very low risk of adverse events and candidate for early hospital discharge or home treatment.Key words: Pulmonary embolism, Prognosis, Biomarkers; PESI, Echocardiography, Bleeding, ESC


  • Open Access

    Prevalence, feature and treatment in a cohort of patients hospitalized for heart failure with preserved systolic function: data from the PRESYF-HF Toscana study

    by Paolo Biagi, Luigi Abate, Salvatore Bocchini, Valerio Verdiani, Carlo Nozzoli

    Background: The prevalence and the characteristics of heart failure (HF) with preserved systolic function (more commonly named diastolic heart failure) may differ according to the type of the study (population based or cohort), setting, methods to define the cardiac function, so epidemiologic data are actually quite variable ranging from 15% to over 60% of HF patients. Moreover the treatment is still based more on physiopathologic data of the single case for no evidence based therapy has been defined. Materials and methods: We have studied a cohort of 338 consecutive patients admitted for HF at 24 Internal Medicine Units; all patients had a left ventricular ejection fraction (LVEF) echographically measured within 72 hours from hospital admission. Patients with LVEF > 50% were considered to have preserved systolic function (PRESYF). The prevalence and the clinical characteristics of the patients were recorded as well the therapy at the admission and at the discharge. Pharmacologic treatment was analyzed for each category of drug normalized for equivalent dosage at the admission and at the discharge. Results: The patients with LVEF > 50% were 112 (33.1%); they were older than the subjects with depressed systolic function but the difference in our cohort was not statistically significant; the clinical presentation is similar but female sex, hypertensive ethiology, and elevated BMI prevail. ACE-inhibitors and diuretics are the most frequent drugs prescribed in both forms of HF, with no difference in prescription and dosage at the admission and at the discharge. Beta-blockers were prescribed at a higher dosage in the subjects with depressed than with preserved systolic function (17.86 + 15.90 mg/die vs 9.69 + 9.06 mg/die; p < 0.05). Discussion: One third of patients admitted in hospital for HF has DHF; these patients differ from HF with depressed systolic function for female sex, hypertensive ethiology, and elevated BMI. Taking into account the advanced age of both groups (mean age 81 year) the treatment is aimed above all to control symptoms (actually diuretics are the most used drugs). No difference was registered in prescription and dosage of HF therapy in both forms, with the exception of a wider and a higher dosage of beta-blockers in depressed systolic function. Conclusions: Diastolic HF is a diffuse problem in the real world and account for one third of inhospital admission. Patients are old, complex and present comorbidities. The treatment is still tailored more on single patient physiopathologic data than on evidence base. The prescription ‘‘habits’’ we have registered at the discharge from hospital are the snapshot of what the patients assume in the real world.

  • Pre-Discharge B-Type Natriuretic Peptide Predicts Early Recurrence of Decompensated Heart Failure in Patients Admitted to a General Medical Unit

    by Valerio Verdiani, Carlo Nozzoli, Francesca Bacci, Adriana Cecchin, Maria Serena Rutili, Sergio Paladini, Iacopo Olivotto

    Background: B-type natriuretic peptide (BNP) represents a promising predictor of early (30 days) re-admission in patients with heart failure (HF) admitted to cardiology units. Whether BNP retains its predictive value in unselected patients admitted to general medical wards is unknown. Methods: We determined BNP levels on admission and pre-discharge in 100 consecutive patients (71 male, mean age 78±10 years) admitted to a general medical unit due to decompensated HF. Follow-up after discharge was 30 days. Results: Of the 100 patients, 86 had ≥1 comorbid conditions. Median BNP was 739 pg/ml on admission (25th–75th percentile 355–1333 pg/ml, respectively), and 414 pg/ml pre-discharge (25th–75th percentile 220–696 pg/ml). Seventeen patients were re-admitted or died within 30 days. Patients with pre-discharge BNP values >75th percentile (696 pg/ml) had greater risk of re-hospitalisation, as compared to values ≤696 pg/ml (56% vs. 4%, respectively; p75th percentile were associated with a 15.0 independent relative hazard (RH) of early re-admission or death (95% CI 4.2–53.8; p<0.0001). The other independent predictor was a NYHA class ≥III at discharge (RH 2.9; 95% CI 1.1–9.3; p<0.05). Conclusion: In a general medical unit, pre-discharge BNP levels were a strong independent predictor of early re-admission or death due to HF, irrespective of substantial comorbidity and advanced age.